Clinical trials: Recurrent Tumor
Anaplastic Thyroid Cancer, Relapsed/Refractory Poorly Differentiated Thyroid Cancer
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
The purpose of this study is to assess the safety and tolerability and determine the recommended Phase 2 dose of AIC100 Chimeric Antigen Receptor (CAR) T cells in patients with relapsed/refractory poorly differentiated thyroid…
- Trial name
- NCT04420754
- Testing
- AIC100 CAR T Cells
- Where
- 4 sites in United States
- Volunteers
- 70 people
- Sponsor
- AffyImmune Therapeutics, Inc.
Venous Thromboembolism, Deep Vein Thrombosis (DVT)
Comparative Investigation of Low Molecular Weight (LMW) Heparin/Edoxaban Tosylate (DU176b) Versus (LMW) Heparin/Warfarin in the Treatment of Symptomatic Deep-Vein Blood Clots and/or Lung Blood Clots. (The Edoxaban Hokusai-VTE Study).
Evaluation of heparin/edoxaban tosylate (DU176b) versus heparin/warfarin in preventing recurrence of blood clots in patients with acute symptomatic deep-vein blood clots in the legs and/or blood clots in the lungs.
- Conditions
- Venous Thromboembolism, Deep Vein Thrombosis (DVT), Pulmonary Embolism (PE), Thromboembolism
- Trial name
- NCT00986154
- Testing
- edoxaban tosylate(DU-176b), low molecular weight heparin/unfractionated heparin, warfarin
- Where
- 454 sites in United States, Argentina and 36 more
- Volunteers
- 8,292 people
- Sponsor
- Daiichi Sankyo
Squamous Cell Carcinoma of the Oropharynx
A Phase II Study of Cemiplimab and ISA101b in Patients With Recurrent/Metastatic HPV16 Positive OPC
This will be an open-label, phase 2 study in which subjects will receive ISA101b and cemiplimab.
- Trial name
- NCT04398524
- Testing
- ISA101b
- Where
- 41 sites in United States, Belgium and 7 more
- Volunteers
- 65 people
- Sponsor
- ISA Pharmaceuticals
Advanced Solid Tumors, Recurrent Solid Tumors
ONO-4538 Phase I Study in Patients With Solid Tumor
The objective of the study is to investigate the pharmacokinetics of ONO-4538 administered to Korean patients with advanced or recurrent solid tumors who are refractory or intolerant to standard therapy or for whom no appropriate…
- Trial name
- NCT02261285
- Testing
- ONO-4538
- Where
- 5 sites in South Korea
- Volunteers
- 18 people
- Sponsor
- Ono Pharmaceutical Co., Ltd.
Glioma, Glioma, Malignant
Study of NUV-422 in Adults With Recurrent or Refractory High-grade Gliomas and Solid Tumors
At the time of study termination, NUV-422-02 was a first-in-human, open-label, Phase 1 dose escalation study designed to evaluate the safety and efficacy of NUV-422.
- Conditions
- Glioma, Glioma, Malignant, Glioma, Mixed, Glial Cell Tumors
- Trial name
- NCT04541225
- Testing
- NUV-422
- Where
- 12 sites in United States
- Volunteers
- 74 people
- Sponsor
- Nuvation Bio Inc.
Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive)
A Study of NDV-01 as an Intravesical Administration to Patients With BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (NMIBC), Refractory to First-line Therapy
This is a Phase 3, open-label single-arm trial designed to evaluate the safety and efficacy of NDV-01 (sustained-release gemcitabine-docetaxel) in adult participants with NMIBC with CIS who have failed BCG therapy and who have…
- Conditions
- Bladder (Urothelial, Transitional Cell) Cancer, Bladder (Urothelial, Transitional Cell) Cancer Superficial (Non-Invasive), Urothelial Carcinoma Bladder, Urothelial Carcinoma Recurrent
- Trial name
- RESCUE (NCT07342517)
- Testing
- NDV-01 (sustained-release gemcitabine-docetaxel)
- Volunteers
- healthy volunteers welcome
- Sponsor
- Relmada Therapeutics, Inc.
NHL, Adult, AML, Adult Recurrent
A Phase I Study of Euthare-155008(ETH-155008) in AML and NHL Patients
This Trial is an open-label, multicenter trial to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ETH-155008 in subjects with AML and NHL who previously received standard treatment or are…
- Trial name
- NCT05758610
- Testing
- ETH-155008
- Where
- 2 sites in China
- Volunteers
- 60 people
- Sponsor
- Shengke Pharmaceuticals (Jiangsu) Limited, China
Solid Tumor
Autologous Tumor-infiltrating Lymphocyte Injection (GT201) for the Treatment of Metastatic/Recurrent Advanced Solid Tumors
This study is a single-center, single-arm phase I clinical trial. A total of 30 subjects (20 evaluable cases are expected) from 1 cohort will be enrolled in this study.
- Trial name
- GT201 (NCT05430360)
- Testing
- GT201
- Where
- China
- Volunteers
- 2 people
- Sponsor
- Grit Biotechnology
Pediatric Oncology
A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy
Dose escalation phase of the study : To define the safety profile, maximum tolerated dose (MTD) and recommended phase II dose (RP2D) of regorafenib administered orally as a single agent in a 3-weeks-on/1- week-off schedule in…
- Trial name
- NCT02085148
- Testing
- Regorafenib (BAY73-4506), Vincristine (Cellcristin®), Irinotecan (Irinotecan Cell pharm®)
- Where
- 12 sites in France, Italy and 2 more
- Volunteers
- 62 people
- Sponsor
- Bayer
Non-squamous Non-small-cell Lung Cancer
A Study Exploring Efficacy of SIBP04 in Subjects With Non-squamous Non-small Cell Lung Cancer
This trial is a randomized, double-blind, parallel-controlled, multicenter phase III clinical study. To evaluate the clinical efficacy of SIBP04 in patients with locally advanced, metastatic or recurrent non-squamous non-small…
- Trial name
- NCT05318443
- Testing
- SIBP04, Avastin, Paclitaxel
- Where
- China
- Volunteers
- 512 people
- Sponsor
- Shanghai Institute Of Biological Products
Ovarian Cancer
Chiauranib in Combination With Chemotherapy in Patients With Ovarian Cancer
This clinical trial will evaluate the efficacy and safety of chiauranib added to chemotherapy in patients with relapsed or refractory ovarian cancer, in the meantime, explore the pharmacokinetics characteristic after the combined…
- Trial name
- NCT03901118
- Testing
- chiauranib, etoposide, paclitaxel
- Where
- China
- Volunteers
- 47 people
- Sponsor
- Chipscreen Biosciences, Ltd.
Lymphoma, Non-Hodgkin, Lymphoma, Follicular
Open-label Study of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Auriхim
This is an open-label study of safety, tolerability, pharmacokinetics and pharmacodynamics of Auriхim multiple doses in patients with recurrent/ refractory В-cell, CD20-positive non-Hodgkin lymphoma of low tumor grade or with…
- Trial name
- NCT03057418
- Testing
- Aurixim
- Where
- 3 sites in Russia
- Volunteers
- 7 people
- Sponsor
- Biointegrator LLC
Non-Hodgkin's Lymphoma, Relapsed Lymphoma
Phase II Gallium Nitrate in Relapsed or Refractory Non-Hodgkin's Lymphoma
Eligible patients will have low- or intermediate-grade Non-Hodgkin's Lymphoma (NHL) that has progressed after standard chemotherapy.
- Conditions
- Non-Hodgkin's Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Low-Grade Lymphoma
- Trial name
- NCT00054808
- Testing
- gallium nitrate
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Genta Incorporated
Locally Advanced Breast Cancer, Metastatic Breast Cancer
A Study of the Efficacy, Safety and Pharmacokinetics of RPH-051 and Perjeta® in Combination With Trastuzumab and Docetaxel as the 1st Line Therapy in Patients With HER2-positive Breast Cancer
The main purpose of this study is to prove non-inferiority, as well as to demonstrate the comparability of safety and immunogenicity of RPH-051 and Perjeta® in combination with trastuzumab and docetaxel as the 1st line therapy…
- Trial name
- NCT07386938
- Testing
- RPH-051, Docetaxel, Perjeta®
- Where
- 45 sites in Russia
- Volunteers
- 246 people
- Sponsor
- R-Pharm
Recurrent Glioblastoma Multiforme
Phase 2 Study of Panzem Nanocrystal Colloidal Dispersion (NCD) in Combination With Fixed-Dose Temozolomide to Patients With Recurrent Glioblastoma Multiforme (GBM)
The purpose of this study is to evaluate the anti-tumor activity and safety of Panzem NCD given in combination with daily oral fixed-dose temozolomide in patients with recurrent glioblastoma multiforme.
- Trial name
- NCT00481455
- Testing
- Panzem NCD, Temozolomide
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- CASI pharmaceuticals, Inc.
Relapsed or Plateau-Phase Multiple Myeloma
Open-Label, Phase 2, Proof of Concept Study in Multiple Myeloma - Denosumab
The purpose of this study is to determine if denosumab is effective in the treatment of relapsed or plateau-phase multiple myeloma.
- Trial name
- NCT00259740
- Testing
- DENOSUMAB
- Volunteers
- 96 people
- Sponsor
- Amgen
Prostate Cancer
Study of 18F-DCFPyL PET/CT Imaging in Patients With Prostate Cancer
This study evaluates the safety and diagnostic performance of 18F-DCFPyL Injection in patients with at least high risk prostate cancer who are planned for radical prostatectomy with lymphadenectomy (Cohort A) or in patients with…
- Trial name
- OSPREY (NCT02981368)
- Testing
- 18F-DCFPyL Injection, PET/CT imaging
- Where
- 10 sites in United States, Canada
- Volunteers
- 385 people
- Sponsor
- Progenics Pharmaceuticals, Inc.
Ovarian Cancer, Colorectal Cancer
EMD 273066 in Patients With Recurrent EpCAM Positive Ovarian, Prostate, Colorectal or Non-small Cell Lung Cancers When First Given Cyclophosphamide
This study is looking at the safety and tolerability of the experimental biological drug EMD 273066 when given with low dose cyclophosphamide to patients with recurring EpCAM positive ovarian, prostate, colorectal or non-small…
- Conditions
- Ovarian Cancer, Colorectal Cancer, Carcinoma, Non-small-cell Lung, Prostate Cancer
- Trial name
- NCT00132522
- Testing
- EMD 273066
- Where
- 5 sites in United States, Switzerland
- Volunteers
- 45 people
- Sponsor
- EMD Serono
Metastatic Breast Cancer, Locally Recurrent Breast Cancer
Bioequivalence Study of IG-001 Versus Nab-paclitaxel in Metastatic or Locally Recurrent Breast Cancer
The purpose of this study is to demonstrate bioequivalence of IG-001 versus nab-paclitaxel in female patients with metastatic or locally recurrent breast cancer.
- Trial name
- TRIBECA (NCT02064829)
- Testing
- Nab-paclitaxel, IG-001
- Where
- 20 sites in United States, Georgia and 5 more
- Volunteers
- 111 people
- Sponsor
- Sorrento Therapeutics, Inc.
Relapsed or Refractory Peripheral T-cell Lymphoma
Chidamide in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (R/R PTCL)
This is a phase II, open-label, non-randomized, single-arm, multicenter study to evaluate the efficacy, safety, and PK of chidamide in patients with R/R PTCL.
- Trial name
- NCT05833724
- Testing
- Chidamide
- Where
- 6 sites in Taiwan
- Volunteers
- 33 people
- Sponsor
- Great Novel Therapeutics Biotech & Medicals Corporation
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.